Aperio to market Definiens Tissue Studio for advanced image analysis
17 May 2011
Digital pathology system supplier Aperio, and image intelligence company Definiens have announced a partnership in which Aperio will market Definiens Tissue Studio, an image analysis product for quantitative digital pathology, on a worldwide, non-exclusive basis.
Image analysis provides automated quantitative analytical techniques to help pathologists interpret pathology slides, which informs treatment decisions and improves patient care.
Definiens Tissue Studio will be integrated into Aperio’s applications framework and accessible through its Spectrum information management system to expand the existing suite of image analysis tools that include Area Quantification, Cell Quantification, Microvessel Analysis, Rare Event Detection and Genie Histology Pattern Recognition. The Spectrum system includes viewing tools and enables the execution of analysis applications in a geographically distributed environment for maximum throughput.
“This alliance furthers our ability to significantly improve intra- and inter-observer agreement and patient care by providing the most scalable and highest performance digital pathology solutions available,” said Dirk G. Soenksen, CEO of Aperio. “We are excited that Definiens recognizes the value of leveraging their leading image analysis software on the industry’s most robust digital pathology platform.”
“Digital pathology is becoming an essential technology for increasing productivity and improving treatment decisions,” said Thomas Heydler, CEO of Definiens. “Automated image analysis is the next step in digital pathology, providing clinicians with greater insight into patients’ disease states. Definiens Tissue Studio is a natural fit for Aperio’s platform, and we expect to reach a wide customer base as a result of this partnership.”